Hematopoietic stem cell transplantation for multiple myeloma beyond 2010

Blood

Volumn 115, Issue 18, 2010, Pages 3655-3663

  Bladé, Joan ^a,b   Rosiñol, Laura ^a   Cibeira, Maria Teresa ^a   Rovira, Montserrat ^a   Carreras, Enric ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERFERON; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ALLOTRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; REVIEW; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE; WHOLE BODY RADIATION; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 77952300504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-238196     Document Type: Review

References (108)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(1):2962-2972.
2. Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol. 2008;20(6):697-704.
3. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica. 2009; 94(2):270-275.
4. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-1999.
5. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5): 2521-2526.
6. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and impact of novel therapies. Blood. 2008;111(5):2516-2520.
7. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced- intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109(8):3588-3594. (Pubitemid 46572554)
8. Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209-216.
9. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927-1929. (Pubitemid 37022595)
10. Barlogie B, Tricot GJ, Van Rhee F, et al. Long-term outcome results of the first tandem auto-transplant trial for multiple myeloma. Br J Haematol. 2006;135(2):158-164. (Pubitemid 44401612)
11. Rovira M, Rosiñol L, Fernández-Avilés F, et al. Is there a curative potential of autologous stem cell transplantation in multiple myeloma? Long-term results from a single institution series. Bone Marrow Transplant. 2009;43[suppl 1]:S147.
12. Koreth J, Cutler SC, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183-196. (Pubitemid 46112369)
13. Barlogie B, Hall R, Zander A, Dicke KA, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986; 67(5):1298-1301. (Pubitemid 16080597)
14. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70(3):869-872. (Pubitemid 18027425)
15. Barlogie B, Jagannath S, Naucke S, et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant. 1998;21(11):1101-1107. (Pubitemid 28256651)
16. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multi-center sequential randomized clinical trial. Blood. 1998;92(9):3131-3136. (Pubitemid 28492319)
17. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84(12):4278-4282. (Pubitemid 24371933)
18. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84(3):950-956. (Pubitemid 24223896)
19. Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30(10):673-679. (Pubitemid 35446649)
20. Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004; 34(2):161-167. (Pubitemid 39077108)
21. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcome with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 2004;34(3):229-234. (Pubitemid 39136829)
22. Bladé J, Rosiñol L, García-Sanz R, et al. A PET-HEMA study of high-dose therapy/stem cell support, including tandem transplant, in primary refractory multiple myeloma (MM): identification of two populations with different outcome. J Clin Oncol. 2007;25[suppl 1]:446a.
23. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97. (Pubitemid 26240110)
24. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348(19):1875-1883. (Pubitemid 36532313)
25. Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood. 2005;106(12):3755-3759. (Pubitemid 41739009)
26. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227-9233. (Pubitemid 46260178)
27. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol. 2006;24(6):929-936. (Pubitemid 46638847)
28. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349(26):2495-2502. (Pubitemid 38010075)
29. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007; 25(17):2434-2441. (Pubitemid 46999214)
30. Bladé J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission: results of a non-randomized study from a single institution. Bone Marrow Transplant. 2000;26(8):845-849.
31. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037-1043. (Pubitemid 32591186)
32. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008; 26(35):5775-5782.
33. van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progressionfree survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399-1406. (Pubitemid 350144158)
34. Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
35. Ladetto M, Pagliano G, Ferrero S, et al. Major tumour shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010 March 22. [Epub ahead of print]
36. Nadal E, Giné E, Bladé J, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant. 2004;33(1):61-64. (Pubitemid 38159705)
37. Dingli D, Pacheco JM, Dispenzieri A, et al. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci. 2007;98(7):1035-1040. (Pubitemid 46865388)
38. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26(3):480-492. (Pubitemid 351171703)
39. San Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26(3):480-492.
40. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;108(1):35-39. (Pubitemid 40967171)
41. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Group. J Clin Oncol. 2006;24(3):431-436. (Pubitemid 46630462)
42. Rajkumar SV, Rosiñol L, Hussein M, et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-2177.
43. Rosiñol L, Cibeira MT, Bladé J, et al. Escape of extramedullary disease to the thalidomide effect in multiple myeloma. Haematologica. 2004;89(7): 832-836. (Pubitemid 38981343)
44. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone plus thalidomide compared with VAD as a pretransplant treatment in newly diagnosed multiple myeloma. Blood. 2006;108(11):22a. Abstract 57.
45. Thomas SK, Giralt SA, Wang M, et al. Survival outcomes of patients receiving thalidomide/dexamethasone for previously untreated multiple myeloma. Blood. 2006;108(11):1019a. Abstract 3569.
46. Lokhorst HM, Bertsch U, Sonneveld P, et al. Thalidomide in indection treatment increases the very good partial response (VGPR) rate before and after high-dose therapy in patients with previously untreated multiple myeloma. Haematologica. 2008;93(1):124-127. (Pubitemid 351156161)
47. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10): 1021-1030. (Pubitemid 43357806)
48. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115-3121.
49. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica. 2006;91(11):1498-1505. (Pubitemid 44736116)
50. Rosiñol L, Oriol A, Mateos MV, et al. A phase II trial of alternating bortezomib and dexamethasone as induction regimen prior to autologous stem cell transplantation in younger patients with multiple myeloma. J Clin Oncol. 2007;25(28): 4452-4458.
51. Harouseau JL, Avet-Loiseau H, Attal M, et al. High complete and very good partial response rate with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM- 2005-01 phase 3 trial. Blood. 2009;114(22):149a. Abstract 353.
52. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141(4):512-516. (Pubitemid 351550543)
53. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12(3):235-236. (Pubitemid 46930250)
54. Cavo M, Tachetti P, Patriarca, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade- thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood. 2008;112(11):65a. Abstract 158.
55. Rosiñol L, Cibeira MT, Martínez J, et al. Thalidomde/ dexamethasone (TD) vs bortezomib- Velcade/thalidomide/dexamethasone vs VBMCP/ VBAD/Velcade as induction therapy prior to autologous stem cell transplantation: first results of a phase III trial from the Spanish PETHEMA group. Blood. 2008;112(11):244a. Abstract 654.
56. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood. 2008; 112(11):41a. Abstract 92.
57. Barlogie B, Anassie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176-185. (Pubitemid 46978271)
58. Mellqvist UH, Lenhoff S, Jhonsen HE, et al. Cyclophosphamide and dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer. 2008;112(1):129-135.
59. Hideshima T, Ikeda H, Chauban D, et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood. 2009; 114(5):1046-1052.
60. Ventura GJ, Barlogie B, Hester JP, et al. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplant. 1990;5(4):265-268. (Pubitemid 20204444)
61. Shimoni A, Smith TL, Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001;27(8):821-828. (Pubitemid 32496415)
62. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999; 23(10):1003-1006.
63. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99(3):731-735.
64. Carreras E, Rosiñol L, Terol MJ, et al. Venoocclusive disease of the liver after high-dose cytoreductive therapy with busulphan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant. 2007;13(12):1448-1454. (Pubitemid 350091380)
65. Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008;14(12):1401-1407.
66. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
67. Lonial S, Kaufman J, Langston AA, et al. A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: the effect of sequence of administration. Blood. 2007;110(11):288a. Abstract 949.
68. Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroup Francophone du Myéloma (IFM). Blood. 2010;115(1):32-37.
69. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006; 108(10):3289-3294.
70. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplantation procedure. J Clin Oncol. 2009;27(11):1788-1793.
71. Zangari M, van Rhee F, Anaissie E, et al. Eightyear median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol. 2008;141(4):433-444. (Pubitemid 351550542)
72. Palumbo A, Falco P, Gay F, et al. Bortezomib-doxorubicin- dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood. 2008;112(11):65a. Abstract 159.
73. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood. 2006;108(11):123a. Abstract 403.
74. Dingli D, Pacheco JM, Nowakowski GS, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol. 2007; 25(31):4933-4937. (Pubitemid 350220425)
75. Hoering A, Crowley J, Shaughnessy JD Jr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood. 2009;114(7):1299-1305.
76. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107(2):431-434. (Pubitemid 43076361)
77. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196-1198.
78. Alyea E, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003;32(12):1145-1151. (Pubitemid 38072327)
79. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13: 1312-1322.
80. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors and outcome. Blood. 1996;88(7):2787-2793. (Pubitemid 26327535)
81. Gahrton G, Iacobelli S, Bandini G, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica. 2007;92(11):1513-1518. (Pubitemid 350144127)
82. Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study Hovon 24 MM. J Clin Oncol. 2003;21(9):1728-1733.
83. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004; 103(11):4362-4364. (Pubitemid 38685385)
84. Bellucci R, Wu CJ, Chiaretti S, et al. Complete response to donor lymphocyte infusions in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004;103(2):656-663. (Pubitemid 38140101)
85. Salama M, Nevill T, Marcellus D, et al. Donor lymphocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000;26(11):1179-1184.
86. Björkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711-4718. (Pubitemid 26419156)
87. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/ melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002;30(6):367-373. (Pubitemid 35203509)
88. Einsele H, Schafer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allograft after reduced-intensity conditioning. Br J Haematol. 2003;121(3):411-418. (Pubitemid 36628332)
89. Pérez-Simón JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol. 2003;121(1):104-108. (Pubitemid 36461275)
90. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma alter reduced intensity conditioning. Exp Hematol. 2003;31(1):73-80. (Pubitemid 36110532)
91. Peggs KS, MacKinnon S, Williams CD, et al. Reduced- intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant. 2003;9(4): 257-265.
92. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Myeloma Working Party of the EBMT. Blood. 2005;105(11):4532-4539. (Pubitemid 40720805)
93. Kröger N, Pérez-Simón JA, Myint H, et al. Relapse to prior autograft and chronic graft-versushost disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10(10):698-708. (Pubitemid 39272874)
94. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002; 100(3):755-760. (Pubitemid 34832597)
95. Kröger N, Cottfried H, Schweerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after reduced intensity conditioning with pre-transplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100(12):3919-3924. (Pubitemid 35402053)
96. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009; 113(14):3383-3391.
97. Bruno B, Rotta M, Patriarca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood. 2009;113(14):3375-3382.
98. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high risk de novo multiple myeloma. Blood. 2006;107(9): 3474-3480.
99. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autograft for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120. (Pubitemid 46425595)
100. Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
101. Cook G, Bird JM, Marks DI. In pursuit of the alloimmune response in multiple myeloma: where do we go from here? Bone Marrow Transplant. 2009; 43:91-99.
102. Stewart KA. Reduced-intensity allogeneic transplantation for myeloma: reality bites [editorial]. Blood. 2009;113(14):3135-3136.
103. Kröger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104(10):3361- 3363. (Pubitemid 39507159)
104. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T-lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107(9): 3575-3583.
105. Kröger N, Zabelina T, Ayuk F, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 2006; 34(6):770-775. (Pubitemid 43737100)
106. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma after allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3+ T cells. Leukemia. 2009; 23(3):605-607.
107. Kohrt IE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumour reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; 114(5):1099-1109.
108. Pillai AB, George TI, Dult S, Strober S. Host natural killer T-cells induce an IL-4 dependent expansion of donor CD4+ CD25+ Foxp3+ Tregs that protect against graft-versus-host disease. Blood. 2009;113(18):4458-4467.